Loading
A phase 3 trial of Zimberelimab run by Guangzhou Gloria Biosciences Co., Ltd. in cervical cancer, now recruiting.
A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer is a phase 3 interventional study registered as NCT05798819 by Guangzhou Gloria Biosciences Co., Ltd., with 424 participants planned, started 2023-04-20. Conditions listed: Persistent, Recurrent, or Metastatic Cervical Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Zimberelimab, Recurrent or metastatic cervical cancer, Cervical cancer, Immune checkpoint inhibitors.
Shares Zimberelimab, Immune checkpoint inhibitors.
Shares Recurrent or metastatic cervical cancer, Cervical cancer, Immune checkpoint inhibitors.
Shares Recurrent or metastatic cervical cancer, Cervical cancer, Immune checkpoint inhibitors.
Shares Recurrent or metastatic cervical cancer, Cervical cancer.
Shares Recurrent or metastatic cervical cancer, Cervical cancer.
Shares Recurrent or metastatic cervical cancer, Cervical cancer, Immune checkpoint inhibitors.
Shares Recurrent or metastatic cervical cancer, Cervical cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/